david ilson, md, phd, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in her2 mega
Published 5 years ago • 87 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
0:27
john strickler, md, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mega
-
1:08
david ilson, md, phd, on how we can individualize treatment of gastroesophageal cancer patients
-
2:09
david ilson, md, phd, on the use of biomarkers in the treatment of esophagogastric cancer
-
0:51
david ilson, md, phd, considers how to assess response in gastroesophageal cancer patients
-
2:14
dr. ilson on the future treatment paradigm of gastric cancers
-
1:54
david siegel, md, phd, on pembrolizumab and lenalidomide in multiple myeloma treatment
-
8:11
cervical & lumbar medial branch neurotomy - david impastato, m.d.
-
1:14:02
spondyloarthritis treatment & research presented by james rosenbaum, md
-
4:42
what is the optimal place in the myeloma treatment algorithm for bispecifics?
-
2:27
addressing the unmet needs for patients with tp53-mutated aml
-
1:10
emerging evidence on gepants and medication overuse headache
-
1:14
dr. ilson discusses the findings of the rtog 0436 trial
-
0:30
la jolla scientist awarded first nobel prize of the year
-
6:59
some treatments are eight weeks with one or two pills a day. can it get shorter/easier?
-
3:41
does pd start in the gut
-
2:05
palliative care for people with chronic progressive neurological disease
-
9:26
treatment and treatment decisions - the doctor's perspective
-
2:11
the importance of del(17p) as a prognostic factor in myeloma
-
1:30
dr. david zhuo - cardiology
-
0:13
spot diagnosis skin lesions
-
8:22
multiple myeloma - when doctor becomes a patient.
-
1:23
improved prognosis for patients with multiple myeloma